- Price
- $11.67
- Day
- -6.04%
- Mkt Cap
- $978.43M
- 52W Range
- $9.40 – $19.11
- Volume
- 2.79M
- Beta
- 1.74
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
– COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients ––
Read full article
EyePoint (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Read full article